Harbin Gloria Pharmaceuticals Co., Ltd

Shenzhen Stock Exchange 002437.SZ

Harbin Gloria Pharmaceuticals Co., Ltd Net Income for the year ending December 31, 2023: USD 16.95 M

Harbin Gloria Pharmaceuticals Co., Ltd Net Income is USD 16.95 M for the year ending December 31, 2023, a 140.40% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Harbin Gloria Pharmaceuticals Co., Ltd Net Income for the year ending December 31, 2022 was USD -41.95 M, a -691.84% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Net Income for the year ending December 31, 2021 was USD 7.09 M, a -88.43% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Net Income for the year ending December 31, 2020 was USD 61.29 M, a 116.08% change year over year.
Harbin Gloria Pharmaceuticals Co., Ltd Net Income for the year ending December 31, 2019 was USD -381.25 M, a -2,182.77% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

Shenzhen Stock Exchange: 002437.SZ

Harbin Gloria Pharmaceuticals Co., Ltd

CEO	Mr. Leifeng Guo
IPO Date	Oct. 27, 2011
Location	China
Headquarters	No. 29, Beijing Road
Employees	3,085
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Personal Care

Description

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China.

Key trends

Past 5 years